Search Results - brice+wilson

4 Results Sort By:
Novel Kinase Inhibitory Thiazines
Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including: Oncogenic gene fusion DNAJB1-PRKACA (PKADJ) Wild type protein kinase A (PKA) Protein kinase...
Published: 4/16/2026   |   Updated: 11/4/2024   |   Inventor(s): Barry O'Keefe, Lin Du, Brice Wilson, Ping Zhang, William Moore, Dongdong Wang, Juliana Martinez Fiesco, Ning Li
Keywords(s):  
Category(s): Application, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, TherapeuticArea > Rare/Neglected Diseases
Reverse Thiazine Kinase Inhibitors
Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including: Oncogenic gene fusion DNAJB1-PRKACA (PKADJ) Wild type protein kinase A (PKA) Protein kinase...
Published: 4/16/2026   |   Updated: 10/30/2024   |   Inventor(s): Barry O'Keefe, Lin Du, Brice Wilson, Ping Zhang, William Moore, Dongdong Wang, Juliana Martinez Fiesco, Ning Li
Keywords(s):  
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, TherapeuticArea > Rare/Neglected Diseases
Novel Kinase Inhibitory Aplithianines
Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including: Oncogenic gene fusion DNAJB1-PRKACA (PKADJ) Wild type protein kinase A (PKA) Protein kinase...
Published: 4/16/2026   |   Updated: 10/29/2024   |   Inventor(s): Barry O'Keefe, Lin Du, Brice Wilson, Ping Zhang, William Moore, Dongdong Wang, Juliana Martinez Fiesco, Ning Li
Keywords(s):  
Category(s): Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Rare/Neglected Diseases
Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues
Summary: NCI seeks research co-development partners and/or licensees for the development of recifin and its analogues as new chemosensitizing agents in adjunct therapies with topotecan, irinotecan and related chemotherapeutic agents. Description of Technology: Topoisomerase enzymes play an important role in cancer progression by controlling changes...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Barry O'Keefe, Lauren Krumpe, Johan Rosengren, Ingrid Schroeder, Alan Bermingham, Christophe Marchand, Kirk Gustafson, Brice Wilson, Yves Pommier
Keywords(s): CANCER, Chemosensitizing Agents, CHEMOTHERAPY, Cyclic Peptide, Irinotecan TOP1, O’Keefe, Recifin, Tdp1, Topoisomerase 1 inhibitors, Topotecan, Tyrosyl-DNA Phosphodiesterase 1 Inhibitors
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics